Form 4: Milestone Pharmaceuticals Director Stuart Duty Acquires Stock Options
SEC Form 4 Filing
Director Stuart Duty acquired stock options for 80,000 common shares in Milestone Pharmaceuticals, according to a recent SEC filing.
Summary
- On July 15, 2024, Stuart Duty, a director of Milestone Pharmaceuticals Inc., acquired stock options.
- The options grant the right to buy 80,000 common shares at an exercise price of $1.585 per share.
- The options vest in equal monthly installments over three years, starting August 15, 2024, contingent upon continued service.
- The options expire on July 15, 2034.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects a director's increased stake in the company.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning the interests of management with those of shareholders.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 07/15/2024 | Date of transaction: Stuart Duty acquired stock options. |
| 08/15/2024 | Vesting start date: Options vest in equal monthly installments, beginning on this date, over a three-year period. |
| 07/15/2034 | Expiration date: Stock options expire on this date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.